MElkin Pharmaceuticals is a biopharmaceutical company founded in 2015. It develops innovative synthetic cell-penetrating peptides that inhibit the activation of selective substrates downstream of the intracellular MAP kinases / ERK signaling pathway and thus related cell functions.
Based on research carried out by academic researchers from the Paris-Seine Neuroscience Laboratory (public research organization) of the Paris Seine Institute of Biology (IBPS), these peptides offer a large spectrum of therapeutic applications.
The major objective of the company is to find new treatments for cancer and brain diseases that are associated with aberrant functions of the MAPKinase/ERK signaling pathway.
